In this article
Study Overview: PD-L1 as a Prognostic Marker
The University of Athens Strati A et al. reported that whether PD-L1 is overexpressed in circulating tumor cells (CTC) can provide more feasible and important prognostic information for patients with head and neck squamous cell carcinoma. After treatment, patients with positive PD-L1 in CTC receiving adjuvant PD1 suppression therapy are worth further evaluation. (Ann Oncol. 2017; 28: 1923-1933.)
Based on the tumor’s biological markers, it can be determined whether PD 1 checkpoint inhibitors may ultimately benefit some patients with head and neck squamous cell carcinoma. The molecular characteristics of circulating tumor cells are critical for studying targeted therapy of tumors, and the biomarkers that predict PD 1 checkpoint inhibitors are still unclear. This prospective study included a group of patients with head and neck squamous cell carcinoma who were being treated to evaluate whether circulating tumor cells that overexpress PD-L1 can be detected at baseline (before treatment) and at different treatment time points to predict treatment After the clinical effect.
Methodology: Detecting PD-L1 in Circulating Tumor Cells
The researchers developed a highly sensitive and specific RT-qPCR kit for detecting PD-L1 mRNA expression in EpCAM-positive CTC cells. The study enrolled 113 patients with locally advanced head and neck squamous cell carcinoma and detected PD-L1 expression in EpCAM-positive CTC cells at baseline, after 2 cycles of induction chemotherapy (6 weeks), and after concurrent chemoradiation (15 weeks) Level.
Clinical Findings: Survival Outcomes and Remission Rates
The results showed that at baseline, 25.5% (24/94) patients had PD-L1 overexpression in their CTCs. The rate of overexpression after induction chemotherapy was 23.5% (8/34), and 22.2% (12 /54). After treatment, patients with CTC still overexpressing PD-L1 had shorter progression-free survival (P=0.001) and shorter overall survival (P<0.001).
After treatment, PD-L1 without overexpression may be more likely to achieve complete remission (OR=16, 95%CI 2.76~92.72; P=0.002).
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Alysha Mendossa
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.